Literature DB >> 7468762

The testis in adreno-leukodystrophy.

J M Powers, H H Schaumburg.   

Abstract

Testicular tissue from 7 juvenile and 6 adult patients with adreno-leukodystrophy (ALD) or its adrenomyeloneuropathic (AMN) variant was examined by light and electron microscopy. The seminiferous tubules of the men exhibited hypocellularity, maturation arrest, or Sertoli cells and spermatogonia only. Ultrastructural examination of these specimens revealed vacuolation of Sertoli cell endoplasmic reticulum. Germ cells also demonstrated vacuolation and necrosis, accompanied by slight tubular atrophy and thickening of the tunica propria. Fibrosis or proteinaceous fluid was observed in the interstitium. The tissue of 5 men and 2 boys contained Leydig cells with cytoplasmic striations, which were detectable with the light microscope. A decrease in the number of Leydig cells was noted in some men. All specimens displayed pathognomonic lamellas and lamellar-lipid profiles in mature, immature, or precursor Leydig cells at the ultrastructural level. The Leydig cell demonstrated the primary morphologic defect in the ALD testis; damage to Sertoli cells appeared to be the initial lesion of seminiferous tubules.

Entities:  

Mesh:

Year:  1981        PMID: 7468762      PMCID: PMC1903430     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Adrenoleukodystrophy. A clinical and pathological study of 17 cases.

Authors:  H H Schaumburg; J M Powers; C S Raine; K Suzuki; E P Richardson
Journal:  Arch Neurol       Date:  1975-09

2.  Fatty acid abnormality in adrenoleukodystrophy.

Authors:  M Igarashi; H H Schaumburg; J Powers; Y Kishmoto; E Kolodny; K Suzuki
Journal:  J Neurochem       Date:  1976-04       Impact factor: 5.372

3.  Patho-physiological observations of Sertoli cells in patients with germinal aplasia or severe germ cell depletion. Ultrastructural findings and hormone levels.

Authors:  H E Chemes; M Dym; D W Fawcett; N Javadpour; R J Sherins
Journal:  Biol Reprod       Date:  1977-08       Impact factor: 4.285

4.  Adreno-leukodystrophy (sex-linked Schilder disease). Ultrastructural demonstration of specific cytoplasmic inclusions in the central nervous system.

Authors:  H H Schaumburg; J M Powers; K Suzuki; C S Raine
Journal:  Arch Neurol       Date:  1974-09

5.  Impotence in patients with temporal-lobe lesions.

Authors:  R Hierons; M Saunders
Journal:  Lancet       Date:  1966-10-08       Impact factor: 79.321

6.  The adrenal cortex in adreno-leukodystrophy.

Authors:  J M Powers; H H Schaumburg
Journal:  Arch Pathol       Date:  1973-11

7.  Effects of deficiency of essential fatty acids and treatment with prostaglandin E2 on the ultrastructure of the rat testis.

Authors:  H E Hildebrandt-Stark; D W Fawcett
Journal:  Biol Reprod       Date:  1978-11       Impact factor: 4.285

8.  The peritubular tissue in the normal and pathological human testis. An ultrastructural study.

Authors:  D M de Kretser; J B Kerr; C A Paulsen
Journal:  Biol Reprod       Date:  1975-04       Impact factor: 4.285

9.  Ultrastructural alterations in the seminiferous epithelium of immobilized monkeys.

Authors:  B Gondos; R Zemjanis; A T Cockett
Journal:  Am J Pathol       Date:  1970-12       Impact factor: 4.307

10.  Adreno-leukodystrophy (sex-linked Schilder's disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis.

Authors:  J M Powers; H H Schaumburg
Journal:  Am J Pathol       Date:  1974-09       Impact factor: 4.307

View more
  17 in total

Review 1.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 2.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

3.  Adrenomyeloneuropathy presenting with adrenal insufficiency.

Authors:  Hee Dong Park; Sang Jun Park; Yong Min Choi; Jin Ho Kang
Journal:  Ann Rehabil Med       Date:  2013-08-26

4.  Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.

Authors:  Maria Wichers-Rother; Andreas Grigull; Piotr Sokolowski; Birgit Stoffel-Wagner; Wolfgang Köhler
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

5.  Human sperm tail proteome suggests new endogenous metabolic pathways.

Authors:  Alexandra Amaral; Judit Castillo; Josep Maria Estanyol; José Luís Ballescà; João Ramalho-Santos; Rafael Oliva
Journal:  Mol Cell Proteomics       Date:  2012-11-15       Impact factor: 5.911

Review 6.  Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis.

Authors:  Monika Spurek; Regina Taylor-Gjevre; Stan Van Uum; Hasnain M Khandwala
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

7.  Germ cells of male mice express genes for peroxisomal metabolic pathways implicated in the regulation of spermatogenesis and the protection against oxidative stress.

Authors:  Sandra Dastig; Anca Nenicu; David M Otte; Andreas Zimmer; Jürgen Seitz; Eveline Baumgart-Vogt; Georg H Lüers
Journal:  Histochem Cell Biol       Date:  2011-09-07       Impact factor: 4.304

8.  A missense point mutation (Ser515Phe) in the adrenoleukodystrophy gene in a family with adrenomyeloneuropathy: a clinical, biochemical, and genetic study.

Authors:  M Vorgerd; S Fuchs; M Tegenthoff; J P Malin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

9.  Adrenomyeloneuropathy. A report on two families.

Authors:  J J Martin; A Lowenthal; C Ceuterick; H Gacoms
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

Review 10.  Testosterone-induced effects on lipids and inflammation.

Authors:  Stella Vodo; Nicoletta Bechi; Anna Petroni; Carolina Muscoli; Anna Maria Aloisi
Journal:  Mediators Inflamm       Date:  2013-03-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.